Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy

Gynecologic Oncology

Volumn 110, Issue 2, 2008, Pages 256-264

  Press, Joshua Z ^a   Kenyon, Jennifer A ^a   Xue, Hui ^c   Miller, Melinda A ^b   De Luca, Alessandro ^b   Miller, Dianne M ^a   Huntsman, David G ^b   Gilks, C Blake ^b   McAlpine, Jessica N ^a   Wang, Y Z ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

BRCA genes; Chemotherapy; Ovarian carcinoma; PARP inhibitor; Xenograft mouse model

Indexed keywords

CARBOPLATIN; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CLUSTER ANALYSIS; GENE MUTATION; GENETIC STABILITY; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CAPSULE; MITOSIS INDEX; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; ONCOGENE; OVARY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; SCID MOUSE; STAINING; TUMOR VOLUME; TUMOR XENOGRAFT; UTERUS SARCOMA;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BASE SEQUENCE; CARBOPLATIN; EXONS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENITAL NEOPLASMS, FEMALE; GERM-LINE MUTATION; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY; MICE; MICE, INBRED NOD; MICE, SCID; MOLECULAR SEQUENCE DATA; NEOPLASM TRANSPLANTATION; NUCLEIC ACID HYBRIDIZATION; PACLITAXEL; POLY(ADP-RIBOSE) POLYMERASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 48949115574     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.03.011     Document Type: Article

References (25)

1. Cannistra S.A. Cancer of the ovary. N Engl J Med 351 (2004) 2519-2529
2. Giuntoli II R.L., Metzinger D.S., DiMarco C.S., Cha S.S., Sloan J.A., Keeney G.L., et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol 89 (2003) 460-469
3. Kerbel R.S. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol Ther 2 (2003) S134-S139
4. Buick R.N., Pullano R., and Trent J.M. Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res 45 (1985) 3668-3676
5. Boehm T., Folkman J., Browder T., and O'Reilly M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390 (1997) 404-407
6. Eder Jr. J.P., Supko J.G., Clark J.W., Puchalski T.A., Garcia-Carbonero R., Ryan D.P., et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 20 (2002) 3772-3784
7. Boyd J. Mouse models of gynecologic pathology. N Engl J Med 352 (2005) 2240-2242
8. Lee C.H., Xue H., Sutcliffe M., Gout P.W., Huntsman D.G., Miller D.M., et al. Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. Gynecol Oncol 96 (2005) 48-55
9. Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434 (2005) 913-917
10. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 (2005) 917-921
11. Zorn K.K., Bonome T., Gangi L., Chandramouli G.V., Awtrey C.S., Gardner G.J., et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 11 (2005) 6422-6430
12. Tusher V.G., Tibshirani R., and Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98 (2001) 5116-5121
13. Baldwin R.L., Nemeth E., Tran H., Shvartsman H., Cass I., Narod S., et al. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res 60 (2000) 5329-5333
14. Chan K.Y., Ozcelik H., Cheung A.N., Ngan H.Y., and Khoo U.S. Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer. Cancer Res 62 (2002) 4151-4156
15. Liede A., Karlan B.Y., Baldwin R.L., Platt L.D., Kuperstein G., and Narod S.A. Cancer incidence in a population of Jewish women at risk of ovarian cancer. J Clin Oncol 20 (2002) 1570-1577
16. McCluggage W.G., Lyness R.W., Atkinson R.J., Dobbs S.P., Harley I., McClelland H.R., et al. Morphological effects of chemotherapy on ovarian carcinoma. J Clin Pathol 55 (2002) 27-31
17. Sassen S., Schmalfeldt B., Avril N., Kuhn W., Busch R., Hofler H., et al. Histopathologic assessment of tumor regression after neoadjuvant chemotherapy in advanced-stage ovarian cancer. Hum Pathol 38 (2007) 926-934
18. Le T., Williams K., Senterman M., Hopkins L., Faught W., and Fung-Kee-Fung M. Histopathologic assessment of chemotherapy effects in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking. Gynecol Oncol 106 (2007) 160-163
19. Moynahan M.E., Cui T.Y., and Jasin M. Homology-directed DNA repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res 61 (2001) 4842-4850
20. Boyd J., Sonoda Y., Federici M.G., Bogomolniy F., Rhei E., Maresco D.L., et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. Jama 283 (2000) 2260-2265
21. Turner N., Tutt A., and Ashworth A. Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol 5 (2005) 388-393
22. Scott G.S., Kean R.B., Mikheeva T., Fabis M.J., Mabley J.G., Szabo C., et al. The therapeutic effects of PJ34 [N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide.HCl], a selective inhibitor of poly(ADP-ribose) polymerase, in experimental allergic encephalomyelitis are associated with immunomodulation. J Pharmacol Exp Ther 310 (2004) 1053-1061
23. Mabley J.G., Jagtap P., Perretti M., Getting S.J., Salzman A.L., Virag L., et al. Anti-inflammatory effects of a novel, potent inhibitor of poly (ADP-ribose) polymerase. Inflamm Res 50 (2001) 561-569
24. Garcia Soriano F., Virag L., Jagtap P., Szabo E., Mabley J.G., Liaudet L., et al. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nature medicine 7 (2001) 108-113
25. Press J.P., DeLuca A., Boyd N., Young S., Troussard A., Ridge Y., et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 8 (2008) 17